Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).

Article  CAS  PubMed  Google Scholar 

Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).

Article  PubMed  Google Scholar 

Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017).

Article  CAS  PubMed  Google Scholar 

Kaufman, H. L. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17, 1374–1385 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Migden, M. R. et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med. 379, 341–351 (2018).

Article  CAS  PubMed  Google Scholar 

Oaknin, A. et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET — a phase I, single-arm study. J. Immunother. Cancer 10, e003777 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Mai, H.-Q. et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat. Med. 27, 1536–1543 (2021).

Article  CAS  PubMed  Google Scholar 

Lu, L. et al. Clinically approved combination immunotherapy: current status, limitations, and future perspective. Curr. Res. Immunol. 3, 118–127 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).

Article  CAS  PubMed  Google Scholar 

Gumusay, O., Callan, J. & Rugo, H. S. Immunotherapy toxicity: identification and management. Breast Cancer Res. Treat. 192, 1–17 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sher, A. F., Golshani, G. M. & Wu, S. Fatal adverse events associated with pembrolizumab in cancer patients: a meta-analysis. Cancer Invest. 38, 130–138 (2020).

Article  CAS  PubMed  Google Scholar 

Li, H., van der Merwe, P. A. & Sivakumar, S. Biomarkers of response to PD-1 pathway blockade. Br. J. Cancer 126, 1663–1675 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gopalakrishnan, V. et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).

Article  CAS  PubMed  Google Scholar 

Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).

Article  CAS  PubMed  Google Scholar 

Johnson, D. B. et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer 51, 2792–2799 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Vidotto, T. et al. Emerging role of PTEN loss in evasion of the immune response to tumours. Br. J. Cancer 122, 1732–1743 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trujillo, J. A. et al. Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. J. Immunother. Cancer 7, 295 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Suzman, D. L. et al. FDA Approval Summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist 24, 563–569 (2019).

Article  CAS  PubMed  Google Scholar 

Beaver, J. A. et al. An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies. Clin. Cancer Res. 23, 1368–1372 (2017).

Article  CAS  PubMed  Google Scholar 

Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7, 278 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Twomey, J. D. & Zhang, B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 23, 39 (2021).

Article  PubMed  Google Scholar 

Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

Article  CAS  PubMed  Google Scholar 

Reck, M. et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37, 537–546 (2019).

Article  CAS  PubMed  Google Scholar 

Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).

Article  CAS